These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7747682)

  • 1. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial).
    Waldo AL; Camm AJ; deRuyter H; Freidman PL; MacNeil DJ; Pitt B; Pratt CM; Rodda BE; Schwartz PJ
    Am J Cardiol; 1995 May; 75(15):1023-7. PubMed ID: 7747682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.
    Waldo AL; Camm AJ; deRuyter H; Friedman PL; MacNeil DJ; Pauls JF; Pitt B; Pratt CM; Schwartz PJ; Veltri EP
    Lancet; 1996 Jul; 348(9019):7-12. PubMed ID: 8691967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?
    Pratt CM; Camm AJ; Cooper W; Friedman PL; MacNeil DJ; Moulton KM; Pitt B; Schwartz PJ; Veltri EP; Waldo AL
    Am J Cardiol; 1998 Apr; 81(7):869-76. PubMed ID: 9555777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The azimilide post-infarct survival evaluation (ALIVE) trial.
    Camm AJ; Karam R; Pratt CM
    Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
    Julian DG; Camm AJ; Frangin G; Janse MJ; Munoz A; Schwartz PJ; Simon P
    Lancet; 1997 Mar; 349(9053):667-74. PubMed ID: 9078197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-Sotalol: death by the SWORD or deserving of further consideration for clinical use?
    Doggrell SA; Brown L
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1625-34. PubMed ID: 11060766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J;
    J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
    Advani SV; Singh BN
    Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
    Køber L; Torp-Pedersen C; Carlsen JE; Bagger H; Eliasen P; Lyngborg K; Videbaek J; Cole DS; Auclert L; Pauly NC
    N Engl J Med; 1995 Dec; 333(25):1670-6. PubMed ID: 7477219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable cardiac monitors in high-risk post-infarction patients with cardiac autonomic dysfunction and moderately reduced left ventricular ejection fraction: Design and rationale of the SMART-MI trial.
    Hamm W; Rizas KD; Stülpnagel LV; Vdovin N; Massberg S; Kääb S; Bauer A
    Am Heart J; 2017 Aug; 190():34-39. PubMed ID: 28760211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
    Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
    Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).
    Parkash R; Nault I; Rivard L; Gula L; Essebag V; Nery P; Tung S; Raymond JM; Sterns L; Doucette S; Wells G; Tang ASL; Stevenson WG; Sapp JL
    Circ Arrhythm Electrophysiol; 2018 Jan; 11(1):e005663. PubMed ID: 29305400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
    Auer J; Weber T; Berent R; Puschmann R; Hartl P; Ng CK; Schwarz C; Lehner E; Strasser U; Lassnig E; Lamm G; Eber B;
    Am Heart J; 2004 Apr; 147(4):636-43. PubMed ID: 15077078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving role of sotalol in the management of ventricular tachyarrhythmias.
    O'Callaghan PA; McGovern BA
    Am J Cardiol; 1996 Aug; 78(4A):54-60. PubMed ID: 8780329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure.
    Gottlieb SS; Singh S; Munger M; Eichhorn EJ; Ilgenfritz J; Hanyok J
    Am J Cardiol; 1996 Dec; 78(12):1411-5. PubMed ID: 8970416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.